Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arpida cuts jobs after US iclaprim setback

This article was originally published in Scrip

Executive Summary

Arpidais to cut 60 employees in a restructuring initiative after the US FDAgave a negative recommendation for its extended-spectrum antibiotic iclaprim, for the treatment of severe skin and skin structure infections (Scrip Online, November 21st, 2008). Arpida was surprised and upset by the decision and remained convinced that iclaprim offered a valuable therapeutic asset for the treatment of complicated skin and skin structure infections, especially involving meticillin-resistant Staphylococcus aureus, the company said. It will continue to work with regulatory authorities in the US, Canada and Europe to obtain marketing authorisation and company expects to tell employees of its final decision regarding the restructuring on December 16th.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts